DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 3697--------------------------------------------------
       (Abst.) Nasal foralumab shows promise in nonactive SPMS (CMSC an
       nual meeting)
       By: agate Date: June 27, 2022, 10:45 pm
       ---------------------------------------------------------
       This abstract of a paper presented by researchers at Harvard
       University involves only one patient, but this statement in the
       abstract is worth noting:
       [quote][font=sans-serif]There are no effective treatments for
       non-active secondary progressive MS (SPMS), which is mediated by
       compartmentalized CNS inflammation, including activated
       microglia.[/font][/quote]
       From the recent CMSC conference (June 2, 2022)--"Nasal anti-CD3
       monoclonal antibody (Foralumab) reduces PET microglial
       activation and blood inflammatory biomarkers in a patient with
       nonactive  secondary progressive MS":
  HTML https://cmsc.confex.com/cmsc/2022/meetingapp.cgi/Paper/8395
       From MedPage Today (July 8, 2022), a brief commentary by
       Lawrence Steinman, MD, of Stanford University, on this research.
       The video may not be available but the transcript of his remarks
       is--entitled "Nasal Anti-CD3 Monoclonal Antibody Shows Promise
       in Progressive MS":
  HTML https://www.medpagetoday.com/meetingcoverage/cmscvideopearls/99454
       *****************************************************